These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

723 related articles for article (PubMed ID: 14696757)

  • 1. Epoetin requirement does not depend on dialysis dose when Kt/N > 1.33 in patients on regular dialysis treatment with cellulosic membranes and adequate iron stores.
    Movilli E; Cancarini GC; Vizzardi V; Camerini C; Brunori G; Cassamali S; Maiorca R
    J Nephrol; 2003; 16(4):546-51. PubMed ID: 14696757
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adequacy of dialysis reduces the doses of recombinant erythropoietin independently from the use of biocompatible membranes in haemodialysis patients.
    Movilli E; Cancarini GC; Zani R; Camerini C; Sandrini M; Maiorca R
    Nephrol Dial Transplant; 2001 Jan; 16(1):111-4. PubMed ID: 11209002
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The evaluation of postdialysis L-carnitine administration and its effect on weekly requiring doses of rHuEPO in hemodialysis patients.
    Kadiroglu AK; Yilmaz ME; Sit D; Kara IH; Isikoglu B
    Ren Fail; 2005; 27(4):367-72. PubMed ID: 16060121
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Iron-replete hemodialysis patients do not require higher EPO dosages when converting from subcutaneous to intravenous administration: results of the Italian Study on Erythropoietin Converting (ISEC).
    Pizzarelli F; David S; Sala P; Icardi A; Casani A
    Am J Kidney Dis; 2006 Jun; 47(6):1027-35. PubMed ID: 16731298
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Haemoglobin response to subcutaneous versus intravenous epoetin alfa administration in iron-replete haemodialysis patients.
    Leikis MJ; Kent AB; Becker GJ; McMahon LP
    Nephrology (Carlton); 2004 Jun; 9(3):153-60. PubMed ID: 15189176
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Weekly low-dose treatment with intravenous iron sucrose maintains iron status and decreases epoetin requirement in iron-replete haemodialysis patients.
    Schiesser D; Binet I; Tsinalis D; Dickenmann M; Keusch G; Schmidli M; Ambühl PM; Lüthi L; Wüthrich RP
    Nephrol Dial Transplant; 2006 Oct; 21(10):2841-5. PubMed ID: 16891647
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The kind of vascular access influences the baseline inflammatory status and epoetin response in chronic hemodialysis patients.
    Movilli E; Brunori G; Camerini C; Vizzardi V; Gaggia P; Cassamali S; Scolari F; Parrinello G; Cancarini GC
    Blood Purif; 2006; 24(4):387-93. PubMed ID: 16755161
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease.
    Tsubakihara Y; Nishi S; Akiba T; Hirakata H; Iseki K; Kubota M; Kuriyama S; Komatsu Y; Suzuki M; Nakai S; Hattori M; Babazono T; Hiramatsu M; Yamamoto H; Bessho M; Akizawa T
    Ther Apher Dial; 2010 Jun; 14(3):240-75. PubMed ID: 20609178
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anemia management of adult hemodialysis patients in the US results: from the 1997 ESRD Core Indicators Project.
    Frankenfield D; Johnson CA; Wish JB; Rocco MV; Madore F; Owen WF
    Kidney Int; 2000 Feb; 57(2):578-89. PubMed ID: 10652035
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Erythropoietin requirements: a comparative multicenter study between peritoneal dialysis and hemodialysis.
    Coronel F; Herrero JA; Montenegro J; Fernandez C; Gandara A; Conesa J; Rivera MT; Torrente J; Portolés J; Gomez-Martino JR
    J Nephrol; 2003; 16(5):697-702. PubMed ID: 14733416
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical efficacy of recombinant human erythropoietin in the treatment of anemia in hemodialysis patients: influence of dosing regimen, iron status, and serum aluminum.
    Tsai JC; Lai YH; Tsai ZY; Chien LJ; Tsai JH
    Gaoxiong Yi Xue Ke Xue Za Zhi; 1991 Mar; 7(3):126-35. PubMed ID: 1865507
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current management of anemia in adult hemodialysis patients with end-stage renal disease.
    Frankenfield DL; Johnson CA
    Am J Health Syst Pharm; 2002 Mar; 59(5):429-35. PubMed ID: 11887409
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of dialysis sodium gradient on intradialytic hypertension: an observational study.
    Movilli E; Camerini C; Gaggia P; Zubani R; Feller P; Poiatti P; Pola A; Carli O; Valzorio B; Cancarini G
    Am J Nephrol; 2013; 38(5):413-9. PubMed ID: 24216674
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Guidelines for the treatment of anemia in chronic renal failure].
    Triolo G;
    G Ital Nefrol; 2003; 20 Suppl 24():S61-82. PubMed ID: 14666504
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association between transferrin receptor-ferritin index and conventional measures of iron responsiveness in hemodialysis patients.
    Chen YC; Hung SC; Tarng DC
    Am J Kidney Dis; 2006 Jun; 47(6):1036-44. PubMed ID: 16731299
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intravenous ascorbic acid in hemodialysis patients with functional iron deficiency: a clinical trial.
    Giancaspro V; Nuzziello M; Pallotta G; Sacchetti A; Petrarulo F
    J Nephrol; 2000; 13(6):444-9. PubMed ID: 11132761
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The predictive parameters of erythropoietin hyporesponsiveness in patients on continuous ambulatory peritoneal dialysis.
    Kim JK; Park BS; Park MJ; Choi W; Ma SK; Nah MY; Yeum CH; Jung K; Lee SC; Kim SW; Kim NH; Kang YJ; Choi KC
    Korean J Intern Med; 2001 Jun; 16(2):110-7. PubMed ID: 11590897
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized, controlled study of the consequences of hemodialysis membrane composition on erythropoietic response.
    Richardson D; Lindley EJ; Bartlett C; Will EJ
    Am J Kidney Dis; 2003 Sep; 42(3):551-60. PubMed ID: 12955684
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Subcutaneous epoetin-alpha every one, two, and three weeks in renal anemia.
    Piccoli A; Malagoli A; Komninos G; Pastori G
    J Nephrol; 2002; 15(5):565-74. PubMed ID: 12455725
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Importance of iron supply for erythropoietin therapy.
    Sunder-Plassmann G; Hörl WH
    Nephrol Dial Transplant; 1995 Nov; 10(11):2070-6. PubMed ID: 8643170
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 37.